Carl H. June

Professor

University of Pennsylvania
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Carl H. June is a Professor at the Perelman School of Medicine at the University of Pennsylvania, USA. His research focuses on the development of in vivo CAR T cell generation techniques for the treatment of cancer and autoimmune diseases. Dr. June is recognized for his contributions to immunotherapy and the advancement of cellular therapies in clinical settings.

Articles (23)

Some patients cannot receive T cell therapies because their cells are unable to be manufactured. To address this limitation, we developed K562-based artificial antigen-presenting cells (aAPCs) expressing an OKT3-derived scFv for TCR stimulation, CD86 and 4-1BBL for costimulation, and membrane-bound IL-7 and IL-15Rα/IL-15 for cytokine support. From these aAPCs, we generated cell-derived nanoparticles (CDNPs) that accelerated T cell entry into the cell cycle compared with CD3/28-coated beads, enabling efficient concurrent activation and lentiviral transduction. CDNPs robustly expanded T cells from patients whose products could not be manufactured using standard approaches, and these CDNP-derived CAR T cells controlled tumors in humanized mouse models. In a phase I trial of patients with CD19⁺ malignancies (NCT04684563), cGMP-compatible CDNPs enabled streamlined 3-day manufacturing of IL-18–expressing CD19 CAR T cells, yielding higher cell recovery and durable clinical responses without unexpected toxicities, supporting CDNPs as a platform for commercial CAR T cell production.

Year:

2026

Chimeric antigen receptor (CAR) T cell therapies have transformed treatment of B cell malignancies. However, their broader application is limited by complex manufacturing processes and the necessity for lymphodepleting chemotherapy, restricting patient accessibility. We present an in vivo engineering strategy using targeted lipid nanoparticles (tLNPs) for messenger RNA delivery to specific T cell subsets. These tLNPs reprogrammed CD8 + T cells in both healthy donor and autoimmune patient samples, and in vivo dosing resulted in tumor control in humanized mice and B cell depletion in cynomolgus monkeys. In cynomolgus monkeys, the reconstituted B cells after depletion were predominantly naïve, suggesting an immune system reset. By eliminating the requirements for complex ex vivo manufacturing, this tLNP platform holds the potential to make CAR T cell therapies more accessible and applicable across additional clinical indications.

Year:

2025

Supplemental tables: (1) Subject characteristics. (2) Cytogenetic profiles and high-risk features. (3) Prior treatment exposures and refractoriness. (4) CAR T cell product characteristics. (5) Products that did not meet target dose. (6) Adverse events of grade 3-4. (7) Cytokine release syndrome and ICANS. (8). Maintenance therapy. Supplemental Figures: (1) Study schematic and subject disposition, (2) Correlates of manufacturing success, (3) Hematopoietic recovery, (4) Post-infusion T cell phenotypes, (5) Correlates of in vivo expansion and manufacturing success, (6) Late post-infusion CAR T cell re-expansion, (7) Soluble BCMA, (8) Late-onset clinical responses, (9) MM cell BCMA expression, (10) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA monotherapy patients, (11) Pre- and post-treatment Sox2-specific T cell responses in CART-BCMA + huCART19 combination therapy patients, (12) Sustained post-treatment SOX2-specific T-cell responses.

Year:

2025

Mesothelin is an attractive target for CAR-T therapy on a number of cancer types; however, the efficacy of this therapy is diminished because the bulk of the cell surface-expressed mesothelin is shed through naturally occurring proteolysis leaving behind a short juxtamembrane peptide “stump”. The two problems this creates are (1) the bulk of the target protein is no longer on the tumor cell and (2), the free soluble shed mesothelin remains in the tumor microenvironment and becomes present in blood/other body fluids binding to the mesothelin-targeted CAR-T and interfering with their ability to target the mesothelin that remains on the surface of the tumor. These issues have likely contributed at least in part to the lack of desired efficacy of CAR-T cells that target membrane distal regions of mesothelin (i.e., the shed domain) such as those utilizing anti-mesothelin scFvs SS1 and M5. Here we describe CAR T cells that utilize novel antibodies specific for the mesothelin stump domain thus being unaffected by the natural process of mesothelin shedding. Mesothelin “stump” specific CAR T cells (ST4-22) had cytotoxicity and in vivo activity that was comparable to standard anti-mesothelin CAR T cells. Importantly, CAR T cells expressing ST4-22 were effective against tumor cells that were resistant to standard anti-mesothelin CAR T cells.

Year:

2025

Patients can develop human anti-mouse immune responses against CD19-specific chimeric antigen receptor (CAR) T cells due to the use of a murine CD19-specific single-chain variable fragment to redirect T cells. We screened a yeast display library to identify an array of fully human CD19 single-chain variable fragment binders and performed a series of studies to select the most promising fully human CAR. We observed significant differences in the ability of CARs employing these CD19 binders to be expressed on the cell surface, induce tonic signaling, redirect T-cell function, mediate tumor killing, recognize lower levels of CD19 antigen, and maintain function upon continuous antigen exposure. From this initial analysis, CAR T cells using two binders (42 and 52) were selected for additional studies. Although CAR T cells using both binders controlled tumor growth well in vivo , we advanced a CAR construct using binder 42 for more advanced preclinical testing because of its greater similarity to binders based on the antibody FMC63, which is the murine antibody underlying four FDA-approved CD19-specific CAR T-cell therapies, and ability to robustly respond to tumors expressing lower levels of CD19. We found that this binder uniquely bound CD19 using distinct contact residues than FMC63 and with ∼40-fold lower affinity. CARs using binder 42 were non-inferior to those using the FMC63 binder in a mouse model of acute lymphoblastic leukemia, indicating that CAR T cells using binder 42 should be considered for clinical use.

Year:

2025

Supplemental Figure 4: In the validation titration experiment, the isotype control article was screened for binding against targets identified on the MPA screen as well as the positive controls (Protein A and a known binder CD19), and the negative control (pUC empty Vector) expressed in HEK-293T cells. The isotype control article showed strong binding to Protein A, as expected, there was no binding of the control article to CD19 or any of the other targets evaluated. The isotype control article was screened at four different concentrations, as mentioned at x-axis. Each legend shows the targets that the isotype control article was screened against.

Year:

2025

Supplemental Figure 1: a-b) Primary human T cells stimulated using anti-CD3/28 beads and on the following day were transduced with indicated CARs. Cells were stained with G4S linker antibody (a) and FITC-labeled human CD19 protein (b). c) After 12 days of culture, CAR expression was evaluated using FITC-labeled human CD19 protein.

Year:

2025

Supplemental Figure 3: Anti-CD19 control MAbs HIB19 and CB19 were screened on a CD19 alanine-scan mutation library expressed in HEK 293T cells, with binding assayed by flow cytometry. Binding values are shown as a percentage of the antibodies’ binding to the parental CD19 protein (WT) and represent the mean of at least two replicate data points, with error bars showing half of the range (half of the maximum minus minimum value). The mutations highlighted are ones in which binding of 42 scFv was significantly impaired.

Year:

2025

Supplemental Figure 2: a) Survival curve of mice after CART cell treatment. b-d) Peripheral blood was collected from humanized mice on the indicated days after CART treatment and stained with anti-human CD45, CD3, CD4, CD8 antibodies, and CD19 protein. As indicated, mice were re-challenged with 1M Jeko-1-CBG-GFP 42 days after CART infusion.

Year:

2025

Chimeric antigen receptor (CAR) T-cell therapy has shown remarkable success in the treatment of hematologic malignancies. Unfortunately, it has limited efficacy against solid tumors, even when the targeted antigens are well expressed. A better understanding of the underlying mechanisms of CAR T-cell therapy resistance in solid tumors is necessary to develop strategies to improve efficacy. Here we report that solid tumors release small extracellular vesicles (sEV) that carry both targeted tumor antigens and the immune checkpoint protein PD-L1. These sEVs acted as cell-free functional units to preferentially interact with cognate CAR T cells and efficiently inhibited their proliferation, migration, and function. In syngeneic mouse tumor models, blocking tumor sEV secretion not only boosted the infiltration and antitumor activity of CAR T cells but also improved endogenous antitumor immunity. These results suggest that solid tumors use sEVs as an active defense mechanism to resist CAR T cells and implicate tumor sEVs as a potential therapeutic target to optimize CAR T-cell therapy against solid tumors. Significance: Small extracellular vesicles secreted by solid tumors inhibit CAR T cells, which provide a molecular explanation for CAR T-cell resistance and suggests that strategies targeting exosome secretion may enhance CAR T-cell efficacy. See related commentary by Ortiz-Espinosa and Srivastava, p. 2637

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Collaborators (20)

Alfred Garfall

Assistant Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Edward A. Stadtmauer

University of Pennsylvania

UNITED STATES
View details

Zebin Xiao

Professor

University of Pennsylvania

UNITED STATES
View details

Dan Vogl

Associate Professor of Medicine

University of Pennsylvania

UNITED STATES
View details

Saar I. Gill

University of Pennsylvania

UNITED STATES
View details

Elizabeth Hexner

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details

Joseph A. Fraietta

University of Pennsylvania

UNITED STATES
View details

Gerald Linette

Professor

University of Pennsylvania

UNITED STATES
View details

Xiaowei Xu

Professor

University of Pennsylvania

UNITED STATES
View details

Serge Y. Fuchs

University of Pennsylvania

UNITED STATES
View details

Neil C. Sheppard

PI

University of Pennsylvania

UNITED STATES
View details

Nathan Singh

Assistant Professor

Washington University School of Medicine

UNITED STATES
View details

Meenhard Herlyn

Professor, Director

The Wistar Institute

UNITED STATES
View details

sandra susanibar adaniya

Assistant Professor

University of Pennsylvania

UNITED STATES
View details

Beatriz M. Carreno

University of Pennsylvania

UNITED STATES
View details

Marco Ruella

PI

University of Pennsylvania

UNITED STATES
View details

Wei Guo

University of Pennsylvania

UNITED STATES
View details

James Riley

Professor

University of Pennsylvania

UNITED STATES
View details

Michael Milone

Associate Professor

University of Pennsylvania

UNITED STATES
View details

Adam Cohen

Associate Professor, Clinician-Educator

University of Pennsylvania

UNITED STATES
View details